regardless of positive clinical data, copyright's Vyndamax, a treatment for hereditary transthyretin-mediated amyloidosis (hATTR), is facing significant difficulty from PBMs. The organizations are typically erecting limitations to reimbursement, such as high price restrictions and prior authorization that hinder consumer opportunity. Analysts sugge